Skip to main content
. Author manuscript; available in PMC: 2021 Nov 1.
Published in final edited form as: J Am Acad Dermatol. 2020 May 24;83(5):1239–1253. doi: 10.1016/j.jaad.2020.03.131

Figure 5.

Figure 5.

(A, B) Complete clinicopathologic response at three weeks after the first dose of pembrolizumab in a patient with Merkel cell carcinoma. (C) Findings on histopathology reveal dermal fibrosis and mixed lymphocytic inflammation with negative synaptophysin and chromogranin stains (not shown), both of which were expressed at pre-treatment with pembrolizumab.